Gofen & Glossberg LLC IL Sells 577 Shares of Eli Lilly and Company (NYSE:LLY)

Gofen & Glossberg LLC IL lowered its holdings in Eli Lilly and Company (NYSE:LLYGet Rating) by 2.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,293 shares of the company’s stock after selling 577 shares during the period. Gofen & Glossberg LLC IL’s holdings in Eli Lilly and were worth $6,580,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Cordant Inc. acquired a new stake in Eli Lilly and in the first quarter valued at $25,000. Icapital Wealth LLC acquired a new stake in shares of Eli Lilly and during the 1st quarter worth about $28,000. HWG Holdings LP acquired a new stake in Eli Lilly and in the 4th quarter worth about $28,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Eli Lilly and in the 1st quarter worth about $33,000. Finally, Selective Wealth Management Inc. acquired a new stake in Eli Lilly and in the 1st quarter worth about $33,000. Institutional investors own 82.45% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the transaction, the senior vice president now owns 8,136 shares in the company, valued at $2,477,412. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, SVP Alonzo Weems sold 656 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now owns 8,136 shares in the company, valued at approximately $2,477,412. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 177,243 shares of the company’s stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $330.28, for a total transaction of $58,539,818.04. Following the completion of the sale, the insider now owns 103,983,810 shares of the company’s stock, valued at approximately $34,343,772,766.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 328,125 shares of company stock worth $108,581,151. Insiders own 0.12% of the company’s stock.

Eli Lilly and Stock Up 4.9 %

Eli Lilly and stock opened at $310.87 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. Eli Lilly and Company has a 12-month low of $220.20 and a 12-month high of $335.33. The firm’s fifty day moving average is $314.33 and its 200 day moving average is $304.45. The company has a market capitalization of $295.38 billion, a PE ratio of 49.58, a PEG ratio of 1.92 and a beta of 0.38.

Eli Lilly and (NYSE:LLYGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company had revenue of $6.49 billion for the quarter, compared to analyst estimates of $6.85 billion. During the same quarter in the previous year, the firm earned $1.87 EPS. The firm’s revenue was down 3.7% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were issued a dividend of $0.98 per share. The ex-dividend date was Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.26%. Eli Lilly and’s payout ratio is 62.52%.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Citigroup lifted their price objective on shares of Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. Barclays raised their target price on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, July 7th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. StockNews.com raised shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 14th. Finally, BMO Capital Markets raised their target price on shares of Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a report on Tuesday, September 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $332.19.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.